CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Of 160 treated patients (59 with nivolumab 3 mg/kg, 49 with nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, 52 with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg), 79% had received two or more prior therapies. At the data cutoff, investigator-assessed objective response rates were 12% (95% CI, 5% to 23%), 24% (95% CI, 13% to 39%), and 8% (95% CI, 2% to 19%) in the three groups, respectively. Responses were observed regardless of tumor programmed death-ligand 1 status. With a median follow-up of 28, 24, and 22 months across the three groups, 12-month progression-free survival rates were 8%, 17%, and 10%, respectively; 12-month OS rates were 39%, 35%, and 24%, respectively. Treatment-related grade 3/4 adverse events were reported in 17%, 47%, and 27% of patients in the three groups, respectively. CONCLUSION:
|
Authors | Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Padmanee Sharma, Patrick A Ott, Katriina Peltola, Dirk Jaeger, Jeffry Evans, Filippo de Braud, Ian Chau, Christopher T Harbison, Cecile Dorange, Marina Tschaika, Dung T Le |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 36
Issue 28
Pg. 2836-2844
(10 01 2018)
ISSN: 1527-7755 [Electronic] United States |
PMID | 30110194
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy, mortality)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Esophageal Neoplasms
(drug therapy, mortality)
- Esophagogastric Junction
(pathology)
- Female
- Humans
- Ipilimumab
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Nivolumab
(administration & dosage, adverse effects)
- Progression-Free Survival
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|